Lercanidipina Sandoz (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in the smooth muscle of arterial walls. This inhibition prevents calcium‑mediated contraction, causing vasodilation of peripheral vessels. The resulting decrease in systemic vascular resistance leads to a reduction in arterial blood pressure.

The appropriate dose is determined by the prescribing clinician based on the individual’s blood pressure, response to therapy, and any co‑existing medical conditions. Physicians typically start with a low dose and may adjust it to achieve target blood pressure while monitoring for tolerability.

Safety data for lercanidipine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required cold‑chain handling), and import documentation.

Lercanidipine belongs to the dihydropyridine class of calcium‑channel blockers, offering potent vasodilation with a relatively long half‑life, which allows once‑daily dosing. Compared with ACE inhibitors or beta‑blockers, it primarily reduces peripheral resistance without affecting heart rate, making it suitable for patients who need strong arterial relaxation but may be less effective in conditions requiring heart‑rate control.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister or container, protect from moisture and direct light, and ensure the packaging remains tightly closed until use.

Lercanidipina Sandoz is taken orally, usually once daily with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious adverse events, although rare, include severe hypotension, hepatic dysfunction, and hypersensitivity reactions such as angioedema or anaphylaxis. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, jaundice, or swelling of the face, lips, tongue, or throat.

Lercanidipina Sandoz is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis, unstable angina, or cardiogenic shock, as the vasodilatory effect may exacerbate these conditions.